• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

AI Platform for Ultrasound Detection of Cardiac Amyloidosis Gets FDA Breakthrough Device Designation


The artificial intelligence (AI)-powered EchoGo Amyloidosis can reportedly detect cardiac amyloidosis by assessing a single echocardiogram.

The Food and Drug Administration (FDA) has granted Breakthrough Device Designation for EchoGo Amyloidosis (Ultromics), which provides artificial intelligence (AI) assessment of echocardiograms to help diagnose cardiac amyloidosis.

While cardiac amyloidosis can be challenging to diagnose due to a heterogenous array of subtypes, including ATTR amyloidosis (transthyretin amyloidosis) and AL amyloidosis (light chain amyloidosis), Ultromics said the EchoGo Amyloidosis modality (developed with support from Janssen Biotech, Inc.) can detect the condition based on one echocardiogram.

Ultromics and Janssen Biotech said the EchoGo Amyloidosis platform is an important innovation in diagnosing a disease that has five-year mortality rates ranging from 44 to 65 percent without early detection.

“While treatments exist to help slow or halt the progression of cardiac amyloidosis, underdiagnosis in the early stages of disease is a huge challenge,” noted Najat Khan, Ph.D., the chief data science officer and global head of Strategy and Operations at Janssen Research and Development, LLC. “When applied to routine tests like echocardiograms, artificial intelligence is demonstrating exciting potential to help facilitate earlier disease detection with the goal of connecting patients with treatment sooner and, ultimately, driving better health outcomes.”

Ultromics noted that EchoGo Amyloidosis platform is intended to be included within the company’s EchoGo Platform. Currently in the midst of preparing regulatory submission of the modality, Ultromics said the EchoGo Amyloidosis platform could receive clearance for commercialization by early 2024.

(Editor’s note: For related content, see “Study Finds AI More Effective Than Sonographer Interpretation of Cardiac Function on Echocardiograms” and “Adjunctive AI Software for Cardiac Ultrasound Gets FDA Nod.”)

Related Videos
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Expediting the Management of Incidental Pulmonary Emboli on CT
Radiology Challenges with Breast Cancer Screening in Women with Breast Implants
Related Content
© 2024 MJH Life Sciences

All rights reserved.